Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
PATIENTS (PTS) SWITCHED TO SARILUMAB FROM ADALIMUMAB ACHIEVE CLINICALLY IMPORTANT IMPROVEMENTS IN RA DISEASE ACTIVITY: RESULTS FROM MONARCH TRIAL OPEN-LABEL EXTENSION (OLE) Burmester, G., Amital, H., Rubbert-Roth, A., van Hoogstraten, H., Gervitz, L., Thangavelu, K., St John, G., Genovese, M. C. BMJ PUBLISHING GROUP. 2019: 1138–39
View details for DOI 10.1136/annrheumdis-2019-eular.4646
View details for Web of Science ID 000472207103323